Roche Unlock the Potential of Locked Nucleic Acids
Hear more from leading author and scientific expert, Dr Bo Rode Hansen at RNA Therapeutics 2017.
London, United Kingdom, October 11, 2016 --(PR.com)-- SMi Group are thrilled to have industry expert Dr Bo Rode Hansen, present a special keynote address on harnessing the potential of locked nucleic acids at the 8th annual RNA Therapeutics conference.
The established event set to take place on 22nd & 23rd February in Central London, will once again gather a global audience of scientific leaders, KOL's and drug development specialists, providing a focal point to discuss the future of targeted drug delivery.
Respected for his extensive RNA experience and involvement in the Locked Nucleic Acid drug platform, Dr Bo Rode Hansen has authored and co-authored over 40 peer reviewed publications. He is currently the Global Head of RNA Therapeutics Research at Roche and General Manager of the Roche Innovation Centre in Copenhagen.
His presentation will provide new insights into RNA therapeutics drug discovery discussing key updates surrounding: drug candidates for diseases with difficult targets; next generation drugs; and new concepts on optimising the drug discovery process.
Dr Bo Rode Hansen will be joining other notable speakers in the field at RNA Therapeutics 2017 including:
John Johnston, Clinical Assessor Biologicals & Biotechnology Unit, MHRA
Jeffrey Ulmer, Head Preclinical Research and Development, GSK Vaccines US
Sanyogitta Puri, Associate Principal Scientist, AstraZeneca
Nagy Habib, Head of Surgery, Co-Founder, Imperial College Healthcare NHS Trust, MiNA Therapeutics
Heinrich Haas, Vice President RNA Formulation & Drug Delivery, BioNTech RNA Pharmaceuticals
Nicole Meisner-Kober, Senior Investigator, RNA Biology, Novartis Institutes for Biomedical Research
David Giljohann, CEO, Exicure
Shai Erlich, Chief Medical Officer & President USA, Quark Pharmaceuticals Inc
Amotz Shemi, CEO, Silenseed
A detailed agenda and full speaker line-up is available at http://www.therapeutics-rna.com/prcom
Contact Information:
For all media enquiries contact Teri Arri on Tel: +44 (0)20 7827 6162 / Email: tarri@smi-online.co.uk
To register for the conference, visit http://www.therapeutics-rna.com/prcom or contact Fateja Begum on
Tel: +44 (0)20 7827 6184 / Email: fbegum@smi-online.co.uk
To sponsor, speak or exhibit at the conference, contact Alia Malick on Tel: +44 (0)20 7827 6168 /
Email: amalick@smi-online.co.uk
About SMi Group:
Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world's most forward thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk
The established event set to take place on 22nd & 23rd February in Central London, will once again gather a global audience of scientific leaders, KOL's and drug development specialists, providing a focal point to discuss the future of targeted drug delivery.
Respected for his extensive RNA experience and involvement in the Locked Nucleic Acid drug platform, Dr Bo Rode Hansen has authored and co-authored over 40 peer reviewed publications. He is currently the Global Head of RNA Therapeutics Research at Roche and General Manager of the Roche Innovation Centre in Copenhagen.
His presentation will provide new insights into RNA therapeutics drug discovery discussing key updates surrounding: drug candidates for diseases with difficult targets; next generation drugs; and new concepts on optimising the drug discovery process.
Dr Bo Rode Hansen will be joining other notable speakers in the field at RNA Therapeutics 2017 including:
John Johnston, Clinical Assessor Biologicals & Biotechnology Unit, MHRA
Jeffrey Ulmer, Head Preclinical Research and Development, GSK Vaccines US
Sanyogitta Puri, Associate Principal Scientist, AstraZeneca
Nagy Habib, Head of Surgery, Co-Founder, Imperial College Healthcare NHS Trust, MiNA Therapeutics
Heinrich Haas, Vice President RNA Formulation & Drug Delivery, BioNTech RNA Pharmaceuticals
Nicole Meisner-Kober, Senior Investigator, RNA Biology, Novartis Institutes for Biomedical Research
David Giljohann, CEO, Exicure
Shai Erlich, Chief Medical Officer & President USA, Quark Pharmaceuticals Inc
Amotz Shemi, CEO, Silenseed
A detailed agenda and full speaker line-up is available at http://www.therapeutics-rna.com/prcom
Contact Information:
For all media enquiries contact Teri Arri on Tel: +44 (0)20 7827 6162 / Email: tarri@smi-online.co.uk
To register for the conference, visit http://www.therapeutics-rna.com/prcom or contact Fateja Begum on
Tel: +44 (0)20 7827 6184 / Email: fbegum@smi-online.co.uk
To sponsor, speak or exhibit at the conference, contact Alia Malick on Tel: +44 (0)20 7827 6168 /
Email: amalick@smi-online.co.uk
About SMi Group:
Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world's most forward thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk
Contact
SMi Group
Teri Arri
+44 (0) 20 7827 6038
http://www.therapeutics-rna.com/prcom
Teri Arri
+44 (0) 20 7827 6038
http://www.therapeutics-rna.com/prcom
Contact
Categories